- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04029038
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
Phase I/II Study of Dual CD19-CD22 Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced CD19+ CD22+ Lymphoid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the safety of infusion with chimeric antigen receptor T cells targeting CD19 and CD22.
II. To find the recommended phase II dose for recurrent/refractory CD19+CD22+ B cell malignancies.
SECONDARY OBJECTIVES:
I. To describe the overall response rate and complete response rate of relapsed B cell malignancies treated with CAR-T cells targeting CD19 and CD22.
II. To assess other response variables including minimal residual disease (MRD) negative remission, overall survival (OS), and event free survival (EFS).
EXPLORATORY OBJECTIVES:
I. To evaluate the immune reconstitution and persistence of CAR T cells for one year post infusion.
OUTLINE: This is a phase I, dose escalation study of autologous CD19/CD22 chimeric antigen receptor T-cells (CD19-CD22 CAR T cells) followed by a phase II study.
Patients receive standard of care cyclophosphamide intravenously (IV) over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
After completion of study treatment, patients are followed up at 1, 2, 3, 6, and 12 months.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Jin Seon Im
- Phone Number: 832-750-1502
- Email: jim@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Contact:
- Jin Seon Im
- Phone Number: 832-750-1502
- Email: jim@mdanderson.org
-
Principal Investigator:
- Jin Seon Im
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with relapsed/refractory B-acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or non-Hodgkin's lymphoma (NHL) treated with at least two lines of therapy, and have persistent or progressed disease including positive minimal residual disease (MRD)
- Patients may have received last cytotoxic chemotherapy at least 3 weeks prior to lymphodepleting chemotherapy
- Patient may continue targeted therapy until 2 weeks before initiation of lymphodepleting chemotherapy with the exception of ibrutinib
- Disease must be CD19 and/or CD22 positive by flow cytometry or immunohistochemistry
- Karnofsky/Lansky performance scale > 70
- Total bilirubin less than < 1.5 mg/dL except patients with Gilbert syndrome whose total bilirubin must be < 3.0mg/dL
- Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 X upper limit of normal (ULN)
- Alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 5.0 ULN
- Serum creatinine (as estimated by Cockcroft Gault) >= 60 cc/min
- Cardiac ejection fraction >= 50% without evidence of pericardiac effusion as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA), no clinical significant electrocardiogram (ECG) findings
- No clinical significant pleural effusion and baseline oxygen saturation >= 92%
- Absolute lymphocyte count >= 100/ul
- Be able to sign informed consent
- All participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: birth control pills, patches, or injections, intrauterine device (IUD), diaphragm with spermicide, or condom with spermicide. Acceptable forms of birth control for male patients include condom with spermicide. If female participant becomes pregnant during the study, she will be taken off this study. If male participant fathers a child while on study, he must immediately notify his doctor
For patients with history of allogenic stem cell transplantation
- Should not have active acute graft-versus-host disease (GVHD) grade >= 2
- Should not be on immunosuppressants such as tacrolimus, sirolimus, cyclosporine, mycophenolates for a minimum of a month from CD19-CD22 CAR T cell infusion
- Should not be on more than physiologic dose of systemic steroid for adrenal insufficiency (prednisone equivalent 5mg/day)
- Transplantation should be more than 2 months from CD19-CD22 CAR T cell infusion
- Other cell therapy including CAR T cells, donor lymphocyte infusion, virus specific T cells, natural killer (NK) cells, etc should have 6 weeks of wash-out period from the CD19-CD22 CAR T cell infusion
- For patients with history of central nervous system (CNS) disease, CNS disease must be treated prior to enrollment
- For patients with prior treatment history of cell therapy such as other CAR T cells or CAR NK cells or NK cells, cell therapy should have a 6 weeks of wash-out period from CD19-CD22 CAR T cell infusion
- Be able to consent long-term follow-up protocol PA17-0483
Exclusion Criteria:
- Positive beta-human chorionic gonadotropin (hCG) in female of child bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females
- Known positive serology for human immunodeficiency virus (HIV)
- Presence of active grade 3 or greater toxicity from the previous treatment
- Presence of active fungal, bacterial, viral, or other infection requiring IV antibiotics for management
- Presence of active neurologic disorders
- Concomitant use of other investigational agents
- Current use of corticosteroid more than physiological dose for adrenal insufficiency (prednisone equivalent at a dose higher than 10 mg/day)
- Presence of active CNS disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (CD19-CD22 CAR T cells)
Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimal chimeric antigen receptor (CAR) T cell dose level
Time Frame: Up to 30 days
|
Dose-finding will be done using the sequentially adaptive phase I-II EffTox method.
|
Up to 30 days
|
Incidence of adverse events (adverse events)
Time Frame: Up to 30 days
|
Toxicity is defined as a grade 3, 4, or 5 cytokine release syndrome, neurotoxicity, or National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 with onset within 30 days of cell infusion.
Adverse events that are considered disease-related (not suspected of relationship to CD19-CD22 -CAR T cells) will not be considered dose-limiting toxicities.
Only those AEs that occur during the first 30 days after infusion, which are suspected to be related to conditioning lymphodepletion chemotherapy regimen and/or CD19 -CD22-CAR T cells (any component of the treatment regimen), and meet the following criteria, will be used in the definition of toxicity.
Hematologic toxicities will not be considered in the definition of toxicity, as pancytopenia is a common toxicity with this regimen.
|
Up to 30 days
|
Efficacy in complete response (CR) or partial response
Time Frame: Day 30 post cell infusion
|
Efficacy is defined as the patient being alive and in complete response (CR) or partial response (PR) at day 30 post cell infusion.
|
Day 30 post cell infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: Up to 1 year post T-cell infusion
|
Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and T-cell dose level will be evaluated by Bayesian piecewise exponential survival regression.
|
Up to 1 year post T-cell infusion
|
Overall survival
Time Frame: Up to 1 year post T-cell infusion
|
Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and T-cell dose level will be evaluated by Bayesian piecewise exponential survival regression.
|
Up to 1 year post T-cell infusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune reconstitution
Time Frame: Up to 1 year post T-cell infusion
|
These longitudinal values will be evaluated graphically and cross-tabulated with dose.
|
Up to 1 year post T-cell infusion
|
Persistence of CAR T-cells
Time Frame: Up to 1 year post T-cell infusion
|
These longitudinal values will be evaluated graphically and cross-tabulated with dose.
|
Up to 1 year post T-cell infusion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jin S Im, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Neoplastic Processes
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Disease Progression
- Leukemia
- Recurrence
- Lymphoma, Non-Hodgkin
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Neoplasm, Residual
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- 2019-0042 (Other Identifier: M D Anderson Cancer Center)
- P30CA016672 (U.S. NIH Grant/Contract)
- NCI-2019-04229 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progressive Disease
-
Eye Hospital Pristina KosovoEnrolling by invitationProgressive Disease of CorneaeKosovo
-
Atara BiotherapeuticsTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States, Australia, Canada
-
University Hospital, AntwerpHasselt University; University Hospital, Ghent; AZ Sint-Jan AV; National MS Center... and other collaboratorsRecruitingMultiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary-progressive Multiple SclerosisBelgium
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridge; Medical Research Council Mitochondrial Biology UnitCompletedMitochondrial Diseases | Mitochondrial Myopathies | Progressive External Ophthalmoplegia | Progressive Ophthalmoplegia | Progressive; Ophthalmoplegia, External | Mitochondria DNA Deletion | MELASUnited Kingdom
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Hoffmann-La RocheActive, not recruitingProgressive Multiple Sclerosis (PMS)United States, Canada, Brazil, France, Netherlands, Ireland, Germany, Italy, Poland, Russian Federation, Spain, Colombia, Morocco, Hungary, Denmark, Lebanon, Mexico, Costa Rica, Bosnia and Herzegovina, Czechia, Egypt, Guatemala, Panama and more
-
University of Texas at AustinUniversity of California, San Francisco; National Institute on Deafness and...Active, not recruitingPrimary Progressive Aphasia | Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Semantic Memory Disorder | Nonfluent Aphasia, Progressive | Aphasia, ProgressiveUnited States
-
Stanford UniversityKyverna TherapeuticsRecruitingMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary ProgressiveUnited States
-
Novartis PharmaceuticalsTerminatedSecondary Progressive Multiple Sclerosis With Inflammatory Disease ActivitySwitzerland
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia | Logopenic Progressive Aphasia | Non-Fluent Primary Progressive AphasiaUnited States, Canada
Clinical Trials on Cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Centre Oscar LambretCompleted
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted